Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab placebo-controlled phase 3 study in adults with episodic or chronic migraine and inadequate response to prior preventive treatments
2017-002441-30Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fremanezumab in migraine and chronic migraine (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Started Nov 2017; status: completed.
02
Drugs
fremanezumab
03
Conditions
migrainechronic migraine
Beyond the preview
Go deeper on 2017-002441-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002441-30.